Chinese herbal prescriptions for osteoarthritis in Taiwan: analysis of national health insurance dataset

Fang-Pey Chen¹,², Ching-Mao Chang¹, Shinn-Jang Hwang²,³,⁴, Yu-Chun Chen⁴ and Fun-Jou Chen⁵

Abstract

Background: Chinese herbal medicine (CHM) has been commonly used for treating osteoarthritis in Asia for centuries. This study aimed to conduct a large-scale pharmaco-epidemiologic study and evaluate the frequency and patterns of CHM used in treating osteoarthritis in Taiwan.

Methods: A complete database (total 22,520,776 beneficiaries) of traditional Chinese medicine (TCM) outpatient claims offered by the National Health Insurance program in Taiwan for the year 2002 was employed for this research. Patients with osteoarthritis were identified according to the diagnostic code of the International Classification of Disease among claimed visiting files. Corresponding prescription files were analyzed, and an association rule was applied to evaluate the co-prescription of CHM for treating osteoarthritis.

Results: There were 20,059 subjects who visited TCM clinics for osteoarthritis and received a total of 32,050 CHM prescriptions. Subjects between 40 and 49 years of age comprised the largest number of those treated (19.2%), followed by 50-59 years (18.8%) and 60-69 years group (18.2%). In addition, female subjects used CHMs for osteoarthritis more frequently than male subjects (female: male = 1.89: 1). There was an average of 5.2 items prescribed in the form of either an individual Chinese herb or formula in a single CHM prescription for osteoarthritis. Du-zhong (Eucommia bark) was the most commonly prescribed Chinese single herb, while Du-huo-ji-sheng-tang was the most commonly prescribed Chinese herbal formula for osteoarthritis. According to the association rule, the most commonly prescribed formula was Du-huo-ji-sheng-tang plus Shen-tong-zhu-yu-tang, and the most commonly prescribed triple-drug combination was Du-huo-ji-sheng-tang, Gu-sui-pu (Drynaria fortune (Kunze) J. Sm.), and Xu-Duan (Himalaya teasel). Nevertheless, further clinical trials are needed to evaluate the efficacy and safety of these CHMs for treating osteoarthritis.

Conclusions: This study conducted a large scale pharmaco-epidemiology survey of Chinese herbal medicine use in OA patients by analyzing the NHIRD in Taiwan in year 2002.

Keywords: Association rule, Chinese herbal medicine, National health insurance, Osteoarthritis, Pharmaco-epidemiology, Traditional Chinese medicine
Background

Osteoarthritis (OA) is a degenerative joint disease which relates to aging, and affects the joint of hands, hips, knees, spine, and feet [1,2]. OA is the most common form of joint disease in human sparing no race or geographic area [3-5]. It affected 33.6% older people in the United States [6], and the cost of artificial knee and hip replacements for severe OA were $42.3 billion in 2009 [7]. Patients with OA suffered from swelling and pain of joints, limitation of joint motion range, limitation in walking and stair climbing, and lower quality of life [8]. The managements for OA includes weight reduction, rehabilitation, and pharmacologic therapies [9]. The most common western medicine used in treating OA is non-steroidal anti-inflammatory drugs, but some people had adverse drug reactions like gastrointestinal ulcer, bleeding and renal insufficiency [10]. OA is one of the most common musculoskeletal diseases in Taiwan. The incidence rate of OA was 37% among people aged over 50 years old in Taiwan [11].

The etiology of OA is still not fully clear, but the age, genetic, biomechanical, inflammatory, and metabolic changes of joints are the main factors [12,13]. And obesity may alter daily biomechanical exposures and make a damage effects on inflammation in OA joints [14]. Several literatures have elucidated that pro-inflammatory cytokines and anti-inflammatory cytokines like IL-1, IFN-γ, IL-6, IL-7, IL-10 and TNF-α were elevated in the OA joints [15-17]. In addition, the osteoporosis is highly associated with the prevalence of OA in menopausal women [18-20]. And the subchondral bone loss was a feature of osteoporosis and the early stage of OA [21].

Since there are many adverse side effects of conventional western medication in treating OA [22], more and more OA patients use complementary and alternative medicine (CAM) to improve the symptoms and signs of the disease joints [23]. Chinese herbal medicine [24,25], acupuncture [26], dry cupping [27], herbal patch [28] or other CAM therapies [29] were the common CAM widely accepted by OA patients.

National Health Insurance (NHI) is a universal health insurance program executed since 1995 in Taiwan which covers both western medicine and traditional Chinese Medicine (TCM) [30]. Near 98% of all inhabitants in Taiwan were covered in the NHI program at the end of 2002 [31]. However, there were no nationwide population based surveys of CHM used in treating OA so far.

Methods

In this study, we use the complete NHI database of 2002 which covered the entire population of 22,520,776 beneficiaries in Taiwan to survey the utilization and patterns of CHM for TCM outpatients’ clinics.

Data sources

National Health Insurance Research Dataset (NHIRD) is an electronic claim data that contains nationwide medical records of National Health Insurance (NHI) since 1995 in Taiwan. We collected the information including genders, ages, birthdates, dates of encounters, and disease diagnosis of patients from the NHIRD in the year 2002 from outpatient visiting file (CM_CD2002.DAT) and the corresponding prescription files (CM_OO2002.DAT) were also identified. And this study was assessed to the TCM outpatient visits in the NHIRD was approved by the Taipei Veterans General Hospital. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) was used to define the study population with the diagnosis of OA (ICD code: 715). Patients and institutional privacies were protected by scrambling cryptogram. Data of Chinese herbal formulae and Chinese single herbs were provided in prescription files, which could reveal the prescription and the utilization patterns.

The details of NHIRD data have been described in previous prescription patterns and the utilization analysis of CHM in different diseases like insomnia [32], constipation [33], chronic hepatitis [34], inflammatory bowel disease [35], liver cancer [36] and allergic rhinitis [37].

Study design

Although "pattern identification as the basis for determining treatment" is the key concept for treating patients in TCM which is different from that of Western medicine doctors, the TCM doctors in Taiwan still have to use ICD-9-CM codes to make a diagnosis for outpatient visits. Since OA has several types, the ICD-9-CM codes 715.0 (Osteoarthrosis, generalized), 715.1 (Osteoarthrosis, localized, primary), 715.2 (Osteoarthrosis, localized, secondary), 715.3 (Osteoarthrosis, localized, not specified whether primary or secondary), 715.9 (Osteoarthrosis, unspecified whether generalized or localized), 716.1 (Traumatic arthropathy) and 716.9 (Arthropathy, unspecified) were all extracted as target study subjects among the outpatients visits in this study.

Data analysis

We used the Structure Query Language (SQL server 2008, Microsoft Corp., Redmond, WA USA) for data linkage analysis and processing. Frequency and patterns of Chinese formulae or Chinese single herbs use were taken into regular statistics by the Statistical Package for Social Science version 19.0 (SPSS Inc., Chicago, IL USA). Association rule was applied when we used International Business Machines DB2 8.1 (IBM, Armonk, NY USA) for co-prescribing prescriptions. As the support factor and confidence factor were the main determining factors, in this study, we set 0.4% as the minimum support factor and 30% as the minimum confidence level.
Results
There were totally 6,221,426 TCM outpatients (27.6%) treated by CHM among the 22,520,776 beneficiaries under the NHI in 2002. Among these TCM outpatients, 37,163 (0.6%) patients were diagnosed with OA. In this study, we extracted 20,059 patients (54.0%) who visited the TCM outpatient clinics with the single diagnosis of OA. There were totally 32,609 CHM prescriptions for these 20,059 patients. Female patients preferred using CHM for OA more than male patients (female: male = 1.89:1). Patients’ age between 40 and 49 years had the highest prevalence rate (19.2%), followed by age 50-59 years (18.2%), 60-69 years (18.2%) and 70-79 years (15.9%). Table 1 demonstrates the age-sex-specific frequency of CHM used in OA patients.

The top 10 Chinese single herbs for osteoarthritis in CHM were showed in Table 2. Du-zhong (Eucommia ulmoides, 15.6%) was the most common used Chinese single herb, followed by Xu-duan (Dipacus asper, 13.8%), Niu-xi (Achyranthes bidentata, 11.7%), Mu-gua (Chaenomeles lagenaria, 10.1%), Dan-sen (Salvia miltiorrhiza, 9.7%), Ji-xue-teng (Spatholobus suberectus Dunn, 8.5%), Yan-hu-suo (Corydalis yanhusuo, 7.8%), Wei-ling-zian (Clematis asperrima) (7.3%), Ru-xiang (Boswellia carterii Birdw., 5.4%), Mo-yao (Commiphora myrrha Engl., 5.2%) and Gu-sui-pu(Drynaria fortune (Kunze) J. Sm., 4.9%).

Analyzing the prescription pattern of CHM for OA, we found that a patient was given the average of 5.2 CHM in a single prescription. Six items of CHM (20.4%, Figure 1) was the most common CHM prescription with the combination of Chinese herbal formulae or Chinese single herbs, followed by 5 CHMs (19.6%) and 4 CHM combination (15.9%). We used the association rule to evaluate the co-prescription pattern of Chinese formula and Chinese single herb (Table 4 and Table 5). The most common combination of two CHM was “Shu-jia-hou-xie-tang plus Du-huo-ji-sheng-tang”, followed by “Jia-wei-xiao-yao-san plus Du-huo-ji-sheng-tang”, and “Jia-wei-xiao-yao-san plus Shu-jing-huo-zue-tang”.

Discussion
This study is the first nationwide population based survey of the CHM use for OA patients in Taiwan. Females used CHM for OA higher than males (1.89:1), and the female aged 50-69 years had the highest prevalence of CHM use for OA. Menopause, higher percentage of obesity and osteoporosis in female may be the factors accounting for this phenomenon [38-40].

OA patients were treated with the thought of “pattern identification as the basis for determining treatment” by TCM physicians, and the prescriptions were different among TCM doctors according to their individual personal experience and their knowledge of Traditional Chinese herbs. There were few large-scale pharmaco-epidemiologic surveys of OA patients with CHM use. By analyzing the nationwide TCM outpatient clinic medical record from the NHIRD, we can evaluate the utilization and prescription patterns of CHM in treating OA.

### Table 1 Age-sex-specific frequency for the use of Chinese herbal medicines in patients with osteoarthritis under the national health insurance in Taiwan during 2002

| Age (years) | Subjects with osteoarthritis using Chinese herbal medicines |
|-------------|----------------------------------------------------------|
|             | Number of patients (%) | Male (%) | Female (%) |
| <30         | 2,093                  | 9.5%     | 43.8%      | 1,177       | 56.2% |
| 30-39       | 2,681                  | 13.4%    | 35.1%      | 1,741       | 64.9% |
| 40-49       | 3,853                  | 19.2%    | 33.1%      | 2,579       | 66.9% |
| 50-59       | 3,766                  | 18.8%    | 29.6%      | 2,651       | 70.4% |
| 60-69       | 3,654                  | 18.2%    | 29.6%      | 2,619       | 70.4% |
| 70-79       | 3,191                  | 15.9%    | 40.1%      | 1,911       | 59.9% |
| > = 80      | 821                    | 4.1%     | 47.0%      | 435         | 53.0% |
| Total       | 20,059                 | 100.0%   | 34.6%      | 13,113*     | 65.4% |

*male: female = 1:1.89.
The results showed “Du-huo-ji-sheng-tang” was the most common used Chinese herbal formula for OA. Lai et al. [41] conducted a prospective clinical study to observe 68 patients with OA knees who were treated with “Du-huo-ji-sheng-tang” for 4 weeks in 2005. They evaluated the knee condition with the Western Ontario and McMaster Universities Arthritis Index (WOMAC) [42], which is widely used in evaluating knee and hip OA with three dimensions including pain, disability and joint stiffness. They concluded that the WOMAC index scores were decreased after treatment, and the patients’ pain and stiffness in knees were released. In addition, their physical function were improved after treatment. Chen et al. [43] used “Du-huo-ji-sheng-tang”, osaminethacine and placebo in an anterior cruciate ligament transection inducing experimental OA rabbits model, and proposed that histological degeneration of cartilage in “Du-huo-ji-sheng-tang” group was lower than the osaminethacine group and the control group. In this animal model, Du-huo-ji-sheng-tang” could inhibit chondrocytes apoptosis and could also regulate the expression of vascular endothelial growth factor (VEGF) mRNA, hypoxia-inducible factor (HIF) -1α mRNA.

“Shu-jiang-hou-xie-tang” was the second common Chinese herbal formula for OA in this study, and it was also the third common CHM formula in a previous literature [40]. It had been proved to have effects in treating musculoskeletal disease and connective tissue disease [44], and had effects of pain relief with the mechanism of increasing blood circulation in the adjuvant arthritis rats model [45]. The third common Chinese herbal formula was “Dang-gui-nian-tung-tang”, it had been shown to have

The results showed “Du-huo-ji-sheng-tang” was the most common used Chinese herbal formula for OA. Lai et al. [41] conducted a prospective clinical study to observe 68 patients with OA knees who were treated with “Du-huo-ji-sheng-tang” for 4 weeks in 2005. They evaluated the knee condition with the Western Ontario and McMaster Universities Arthritis Index (WOMAC) [42], which is widely used in evaluating knee and hip OA with three dimensions including pain, disability and joint stiffness. They concluded that the WOMAC index scores were decreased after treatment, and the patients’ pain and stiffness in knees were released. In addition, their physical function were improved after treatment. Chen et al. [43] used “Du-huo-ji-sheng-tang”, osaminethacine and placebo in an anterior cruciate ligament transection inducing experimental OA rabbits model, and proposed that histological degeneration of cartilage in “Du-huo-ji-sheng-tang” group was lower than the osaminethacine group and the control group. In this animal model, Du-huo-ji-sheng-tang” could inhibit chondrocytes apoptosis and could also regulate the expression of vascular endothelial growth factor (VEGF) mRNA, hypoxia-inducible factor (HIF) -1α mRNA.

“Shu-jiang-hou-xie-tang” was the second common Chinese herbal formula for OA in this study, and it was also the third common CHM formula for menopause in a previous literature [40]. It had been proved to have effects in treating musculoskeletal disease and connective tissue disease [44], and had effects of pain relief with the mechanism of increasing blood circulation in the adjuvant arthritis rats model [45]. The third common Chinese herbal formula was “Dang-gui-nian-tung-tang”, it had been shown to have

---

**Table 2 The top 10 individual Chinese herbs prescribed for osteoarthritis in Taiwan during 2002 (total prescription numbers = 32,050)**

| Chinese single herb (Chinese name) | Generic name | Number of prescriptions | Percentage |
|-----------------------------------|--------------|-------------------------|------------|
| Du-zhong                          | Eucommia ulmoides | 5,005                  | 15.6%      |
| Xu-duan                           | Dipsacus asper  | 4,419                  | 13.8%      |
| Niu-xi                            | Achyranthes bidentata | 3,763                  | 11.7%      |
| Mu-gua                            | Chaenomeles lagenaria | 3,240                  | 10.1%      |
| Dan-sen                           | Salvia miltiorrhiza | 3,115                  | 9.7%       |
| Ji-xue-teng                       | Spaltholobus suberectus Dunn | 2,721                  | 8.5%       |
| Yan-hu-suo                        | Corydalis yanhusuo | 2,494                  | 7.8%       |
| Wei-ling-xian                     | Clematis chinensis Osbeck | 2,354                  | 7.3%       |
| Ru-xiang                          | Boswellia carteri Birdw. | 1,715                  | 5.4%       |
| Mo-yao                            | Commiphoramyrrha Engl. | 1,674                  | 5.2%       |
| Gu-sui-pu                         | Drynaria fortune (Kunze) J. Sm. | 1,569                  | 4.9%       |

**Table 3 The top 10 Chinese herbal formulae prescribed for osteoarthritis in Taiwan during 2002 (total prescription numbers = 32,050)**

| Chinese herbal formulae (Chinese name) | Ingredients                                                                 | Number of prescriptions (%) |
|---------------------------------------|------------------------------------------------------------------------------|-----------------------------|
| Du-huo-ji-sheng-tang                  | Du-huo, Sang-jin-sheng, Ren-sen, Fu-ling, Gan-cao, Dang-guei, Shao-yao, Chuan-qiong, Di-huang, Gui-zhi, Du-zhong, Niu-xi, Xi-xin, Fang-feng, Qin-jiao | 8,538 (26.6%)               |
| Shu-jiang-hou-xie-tang                | Dang-gue, Gan-cao, Shao-yao, Di-huang, Bai-zhu, Niu-xi, Chen-pi, Tao-ren, Wei-ling-xian, Chuan-qiong, Fang-ji, Qiang-huo, Bai-zhi, Long-dan-cao, Fu-ling, Sheng-jiang | 7,804 (24.3%)               |
| Dang-gui-nian-tung-tang               | Qiang-huo, Yin-jin-hao, Huang-qin, Gan-cao, Zhi-mu, Zhu-ling, Ze-xie, Fang-feng, Dang-guei, Cang-zhu, Ge-gen, Ren-sen, Ku-sen, Sheng-ma, Bai-zhu | 3,560 (11.1%)               |
| Liu-wei-di-huang-wan                  | Di-huang, San-zhu-yu, Shan-yao, Mu-dan-pi, Ze-xie, Fu-ling | 2,779 (8.7%)               |
| Ji-sheng-shen-qi-wan                 | Di-huang, Shan-yao, San-zhu-yu, Ze-xie, Fu-ling, Mu-dan-pi, Rou-gui, Fu-zi, Niu-xi, Che-qian-zi | 2,126 (6.6%)               |
| Chi-po-ti-huang-wan                  | Zhi-mu, Huang-bo, Di-huang, San-zhu-yu, Shan-yao, Ze-xie, Mu-dan-pi, Fu-ling | 2,081 (6.5%)               |
| Kou-qi-di-huang-wan                  | Gou-ci, Ju-hua, Di-huang, San-zhu-yu, Shan-yao, Ze-xie, Mu-dan-pi, Fu-ling | 1,904 (5.9%)               |
| Xue-fu-chu-yu-tang                    | Dang-guei, Di-huang, Tao-ren, Hong-hua, Zhi-shi, Shao-yao, Chai-hu, Gan-cao, Jie-geng, Chuan-qiong, Niu-xi | 1,702 (5.3%)               |
| Gui-zhi-shuo-yao-zhi-mu-tang          | Gui-zhi, Shao-yao, Bai-zhi, Zhi-mu, Ma-huang, Gan-cao, Fang-feng, Sheng-jiang, Fu-zi | 1,532 (4.8%)               |
| Shou-yao-gan-tsao-tang                | Shao-yao, Gan-cao | 1,411 (4.4%)              |
| Jia-wei-xiao-yao-san                 | Dang-guei, Fu-ling, Zhi-zi, Bo-he, Shao-yao, Chai-hu, Gan-cao, Bai-zhu, Mu-dan-pi, Sheng-jiang | 1,249 (3.9%)               |
anti-inflammation and immune regulation effects on experimental OA rats [46].

According to our results, “Du-zhong” was the most common used Chinese single herb in treating OA, and it was also one of the compositions in Du-huo-ji-sheng-tang. In the experiments of ovariectomy-induced rats, it could reduce postmenopausal osteoporosis, body weight, body mass index and fat tissue [47,48]. And “Du-zhong” was also the most common used Chinese single herb in treating osteoporosis in previous publication [40]. Since osteoporosis and osteoarthritis were commonly seen in menopausal and post-menopausal female, the CHM prescriptions for these two diseases were similar. “Xu-dan” was the second most commonly used Chinese single herb for OA. It was shown to increase bone mineral density and also had osteo-protective effect in animal model [49,50]. “Xu-dan” can also improve degeneration of cartilage and bone in the OA mice model [51]. The third common one to treat OA was “Nui-xi”. It could improve bone mineral density and relieve the swelling joint in the OA rat model [52].

Our results showed that the most common combination of two CHMs was “Du-huo-ji-sheng-tang plus Shu-jing-huo-xue-tang” in treating OA, followed by “Jia-wei-xiao-yao-san plus Du-huo-ji-sheng-tang” and “Jia-wei-xiao-yao-san plus Shu-jing-huo-zue-tang.” “Jia-

Table 4 The most common prescription patterns for combination Chinese herbs in a single prescription for subjects with osteoarthritis in Taiwan during 2002 (total prescription numbers = 32,050)

| Chinese herbal formulae or single herbs                              | Support (%) | Number of prescriptions |
|---------------------------------------------------------------------|-------------|------------------------|
| Shen-tung-chu-yu-tang, Du-huo-ji-sheng-tang                         | 0.7%        | 236                    |
| Jia-wei-xiao-yao-san, Du-huo-ji-sheng-tang                         | 0.6%        | 197                    |
| Jia-wei-xiao-yao-san, Shu-jing-huo-xue-tang                        | 0.6%        | 189                    |
| Gui-zhi-shuo-yao-zhi-mu-tang, Ji-xue-teng                          | 0.5%        | 154                    |
| Che-qian-zhi, Du-huo-ji-sheng-tang                                 | 0.5%        | 152                    |
| Suan-zao-ren, Shu-jing-huo-xue-tang                                | 0.5%        | 149                    |
| Tao-ren, Du-huo-ji-sheng-tang                                      | 0.4%        | 137                    |
| Ye-jiao-teng, Shu-jing-huo-xue-tang                                | 0.4%        | 136                    |
| Ge-gen, Ji-ju-di-huang-wan                                         | 0.4%        | 136                    |
| Ge-gen, Xue-fu-chu-yu-tang                                         | 0.4%        | 132                    |
Table 5 The most common prescription patterns for the triple drug combination of Chinese herbs for subjects with osteoarthritis in Taiwan during 2002 (total prescription numbers = 32,050)

| Chinese herbal formulae or single herbs | Support (%) | Number of prescriptions |
|-----------------------------------------|-------------|------------------------|
| Du-huo-ji-sheng-tang, Gu-sui-pu, Xu-duan | 0.9%        | 154                    |
| Du-huo-ji-sheng-tang, Yan-hu-suo, Niu-xi | 0.4%        | 133                    |
| Du-huo-ji-sheng-tang, Shu-jing-huo-xue-tang, Yan-hu-suo | 0.4% | 132 |
| Du-zhong, Xu-duan, Gu-sui-pu. | 0.4%        | 130                    |
| Du-zhong, Wei-ling-xian, Xu-duan | 0.4%        | 124                    |
| Du-huo-ji-sheng-tang, Shu-jing-huo-xue-tang, Wei-ling-xian | 0.4% | 123 |
| Du-huo-ji-sheng-tang, Wei-ling-xian, Xu-duan | 0.4% | 118 |
| Du-huo-ji-sheng-tang, Wei-ling-xian, Niu-xi | 0.4% | 113 |
| Du-zhong, Xu-duan, Ji-xue-teng | 0.3%        | 107                    |
| Ji-sheng-ten-qian-wan, Du-zhong, Mu-gua | 0.3%        | 106                    |

Conclusions
This pharmaco-epidemiological study showed higher utilization of Chinese herbal medicine use of OA patients in the 40-49 age group and female patients, with Du-zhong (Eucommia bark) and Du-huo-ji-sheng-tang being the most commonly prescribed single herb and herbal formula, respectively.

The most common single herb and Chinese herbal formula are “Du-zhong” and Chinese “Du-huo-ji-sheng-tang.” The most common combination of two CHMs and triple CHMs are “Shu-jiang-hou-xie-tang plus Du-huo-ji-sheng-tang” and “Du-huo-ji-sheng-tang, Gu-sui-pu plus Xu-duan.” However, the therapeutic effects and safety of these CHM in treating OA still need to elucidate with well-defined randomized, double-blind, placebo-controlled clinical trials for further study.

Abbreviations
CHM: Chinese herbal medicine; TCM: Traditional Chinese medicine; OA: Osteoarthritis; NHII: National Health Insurance; NHIRD: National Health Insurance Research Database; ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification; WOMAC: Western Ontario and McMaster Universities Arthritis Index.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
FPC and SJH conceived and designed the experiments. FPC, YCC and FJC performed the experiments. YCC and FJC analyzed the data. FJC and SJH contributed reagents/materials/analysis tools. FPC, CMC and SJH wrote the manuscript. FPC and SJH conceived the project. All authors read and approved the final manuscript.

Acknowledgments
This study is based on a portion of data from the National Health Insurance Research Database, which is provided by the Bureau of National Health Insurance, Department of Health and managed by National Health Research Institutes in Taiwan. The interpretation and conclusions contained herein do not represent those of Bureau of National Health Insurance, Department of Health or National Health Research Institutes. This study was in part supported by a grant from Ministry of Education, Aim for the Top University Plan as well.
Author details
1. Center for Traditional Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
2. School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
3. Department of Family Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 11217, Beitou District, Taiwan.
4. Department of Research and Education, National Yang-Ming University, I-Lan 26042, Taiwan.
5. School of Chinese Medicine, China Medical University, Taichung 40402, Taiwan.

Received: 26 November 2013 Accepted: 24 February 2014 Published: 7 March 2014

References
1. Osteoarthritis: National clinical guideline for care and management in adults. In: London: Royal College of Physicians of London: 2008.
2. Goldring MR, Chien M: Inflammation in osteoarthritis. Curr Opin Rheumatol 2011, 23(6):471–478.
3. Loeser RF: Aging processes and the development of osteoarthritis. Curr Opin Rheumatol 2013, 25(1):108–113.
4. Martin JA, Buckwalter JA: Aging, articular cartilage chondrocyte senescence and osteoarthritis. Biogerontology 2013, 14(2):257–264.
5. Zhuo Q, Yang W, Chen J, Wang Y: Metabolic syndrome meets osteoarthritis. Nat Rev Rheumatol 2012, 8(12):729–737.
6. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH, National Arthritis Data W: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis & Rheumamism 2008, 58(1):15–25.
7. Murphy L, Helmick CG: The impact of osteoarthritis in the United States: a population-health perspective. Am J Nurs 2012, 112(3 Suppl 1):S13–S19.
8. Firestein GS, Uppal, RC, Gabriel SE, FRCP IBM, MD JROD: Management of primary knee osteoarthritis. Rheumatism-Arthritis Care & Research 2013, 25(1):114–118.
9. Ikegawa S: The genetics of common degenerative skeletal disorders: osteoarthritis and degenerative disc disease. Ann Rev Genomics Hum Genet 2013, 14:246–256.
10. Issa RI, Griffin TM: Pathobiology of obesity and osteoarthritis: integrating biomechanics and inflammation. Pathobiologic Age Rela Dis 2012, 2:17470.
11. Macfarlane RJ, Graham SM, Davies PS, Korres N, Vos, JL, De Vlieger, MJ, van der Heijden, LLH, Netea M, Mantalas, Tisidis E: Anti-inflammatory role and immunomodulation of mesenchymal stem cells in systemic joint diseases: potential for treatment. Expert Opin Ther Targets 2013, 17(3):243–254.
12. Sara-Putjimas P, Cimmino MA, Scarpas R, Castoria, P, Parazzini, F, Zanellini, A, Zanettini, F, Carelli, B: Osteoarthritis: an overview of the disease and its treatment strategies. Semin Arthritis Rheum 2005, 35(1 Suppl 1):1–10.
13. Kapoor M, Martel-Pelletier J, LAjunesse D, Pelletier JP, Fahmi H: Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011, 7(13):331–42.
14. Roux C, Richard I: Early treatments for osteoporosis on osteoarthritis progression. Osteopontin (2012, 23(Suppl 8):881–883.
15. Abo-Allahma D, Nogues X, Javad IA, Huyan A, Arden NK, Azagra R, Cooper C, Adachi JD, Boonen S, Chapurlat RD, Compton, JE, Gehrels SB, Greenspan SL, Hooven FH, Netelenbosj JC, Peelschiff, J, RossiM, Sarnimbik PN, Silverman S, Sins ES, Watts NB, Deez-Perez A: An increased rate of falls at the time of injury: a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW), Annals of the Rheumatic Diseases 2012, 72(6):911–917.
16. Suri P, Morgenoch DC, Hunter, DJ: Epidemiology of osteoarthritis and associated comorbidities. J Infect Dis 2012, 4(5 Suppl 1):510–519.
17. Buhin HE, Lems WF: Osteoarthritis and osteoporosis: what is the overlap? Curr Rheumatol Rep 2013, 15(8):538.
18. Fouladbakhsh J: Complementary and alternative modalities to relieve osteoarthritis symptoms: a review of the evidence on several therapies often used for osteoarthritis management. Orthop Nurs 2012, 31(2):115–121.
19. Brinkhaus B, Witt CM, Jena S, Linde K, Streng A, Hummelsleiberg J, Irnich D, Hammes M, Fiechtner J, Melichar, D: Willich SN: Physician and treatment characteristics in a randomised multicentre trial of acupuncture in patients with osteoarthritis of the knee. Complementary Therapies in Medicine 2007, 15(3):180–189.
20. Teekachunthane S, Kunanunor P, Rojanath Thin, Sanapanich K, Pojcharrarnwiputh S, Lhieochaiphunt S, Praksomak S: Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial [ISRCTN70292892]. BMC Compl Altern Med 2004, 4:19.
21. Long L, Soeken K, Ernst E: Herbal medicines for the treatment of osteoarthritis: a systematic review, Rheumatology (Oxford) 2001, 40(7):779–793.
22. Mavrommatis CL, Argyra E, Vadassouka A, Vasiliakos DG: Acupuncture as an adjunctive therapy to pharmaceutical treatment in patients with chronic pain due to osteoarthritis of the knee: a 3-armed, randomized, placebo-controlled trial. Pain 2012, 153(8):1720–1726.
23. Teut M, Kaiser S, Ortz M, Roll S, Ringing S, Willich SN, Brinkhaus B: Pulsatile dry cupping in patients with osteoarthritis of the knee – a randomized, controlled exploratory trial. BMC Compl Altern Med 2012, 12:184.
24. Wang X, Cao Y, Pang J, Du J, Guc C, Liu T, Wei S, Zheng Y, Chen R, Zhan H: Traditional Chinese herbal patch for short-term management of knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Evid Based Compl Alternat Med 2012, 2012:171706.
25. Richmond SJ, Brown SR, Campion PD, Porter AJ, Moffett JA, Jackson DA, Featherstone VA, Taylor AJ: Therapeutic effects of magnetic and copper bracelets in osteoarthritis: a randomised placebo-controlled crossover trial. Compl Ther Med 2009, 17(5):249–256.
26. Cheng SH, Chang TL: The effect of universal health insurance on health care utilization in Taiwan. Results from a natural experiment. J Am Med Assoc 1997, 278(5):889–93.
27. Insurance BNH: National Health Insurance Annual Statistical Report. In: Taipei: Bureau of National Health Insurance, 2001:2002.
28. Chen FP, Jong MS, Chen CY, Kung YY, Chen TJ, Chen FJ, Hwang SJ: Prescriptions of Chinese herbal medicines for insomnia in Taiwan during 2002. Evid Based Compl Alternat Med 2011, 2011:296341.
29. Jong MS, Hwang SJ, Chen YC, Chen TJ, Chen FJ, Chen FP: Prescriptions of Chinese herbal medicine for constipation under the national health insurance in Taiwan. J Chin Med Assoc 2010, 73(7):375–383.
30. Chen FP, Kung YY, Chen YC, Jong MS, Chen TJ, Chen FJ, Hwang SJ: Frequency and pattern of Chinese herbal medicine prescriptions for chronic hepatitis in Taiwan. J Ethnomedicinco 2008, 117(1):84–91.
31. Chen YC, Chen FP, Chen TJ, Chou LC, Hwang SJ: Patterns of traditional Chinese medicine use in patients with inflammatory bowel disease: a population study in Taiwan. Hepatogastroenterology 2008, 55(83–84):467–470.
32. Liao YH, Lin CC, Li TC, Lin JJG: Utilization pattern of traditional Chinese medicine for liver cancer patients in Taiwan. BMC Compl Altern Med 2012, 12:146.
33. Kung YY, Chen YC, Hwang SJ, Chen TJ, Chen FP: The prescriptions frequencies and patterns of Chinese herbal medicine for allergic rhinitis in Taiwan. Allergy 2006, 61(11):1316–1318.
34. Tsai CL, Liu TK: Osteoarthritis in women: its relationship to estrogen and current trends. Life Sci 1992, 50(23):1737–1744.
35. Tsai WL, Yang CY, Lin SF, Fang FM: Impact of obesity on medical problems and quality of life in Taiwan. Am J Epidemiol 2004, 160(5):557–565.
36. Shi YH, Yang YH, Chen PC: Prescription patterns of Chinese herbal products for osteoporosis in Taiwan: a population-based study. Evid Based Compl Alternat Med 2012, 2012:75937.
37. Lai JN, Chen HI, Chen CC, Lin JJH, Hwang JS, Wang JD: Duhuo jisheng tang for treating osteoarthritis of the knee: a prospective clinical observation. Chin Med 2007, 2:4.
38. McConnell S, Kolopak P, Davis AM: The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. Arthritis Rheum Arthritis Care Res 2001, 45(8):543–563.
39. Chen CW, Sun J, Li YM, Shen PA, Chen YQ: Action mechanisms of du-huo-ji-sheng-tang on cartilage degradation in a rabbit model of osteoarthritis. Evid Based Compl Alternat Med 2011, 2011:17479.
40. Yang YH, Chen PC, Wang JD, Lee CH, Lai JN: Prescription pattern of traditional Chinese medicine for climacteric women in Taiwan. Climacteric 2009, 12(6):541–547.
45. Kanai S, Taniguchi N, Higashino H: Study of sokei-kakketu-to (shu-jing-huo-xue-tang) in adjuvant arthritis rats. *Am J Chin Med* 2003, 31(6):879–884.

46. Chun-juan X, Rong C: Research progress of Danggui Niantong Tang. *Ch J Exp Tradit Med Formulae* 2010, 06:281–283.

47. Zhang R, Liu ZG, Li C, Hu SJ, Liu L, Wang JP, Mei QB: Du-Zhong (Eucommia ulmoides Oliv.) cortex extract prevent OVX-induced osteoporosis in rats. *Bone* 2009, 45(3):553–559.

48. Zhang W, Fujikawa T, Mizuno K, Ishida T, Ooi K, Hirata T, Wada A: Eucommia leaf extract (ELE) prevents OVX-induced osteoporosis and obesity in rats. *Am J Chin Med* 2012, 40(4):735–752.

49. Liu M, Xiao GG, Rong P, Zhang Z, Dong J, Zhao H, Li H, Li Y, Pan J, Liu H, Wang W, Zha Q, Ju C: Therapeutic effects of Radix Dipsaci, Pyrola Herb, and Cynomorium Songaricum on bone metabolism of ovariectomized rats. *BMC Complementary and Alternative Medicine* 2012, 12(1):67.

50. Liu ZG, Zhang R, Li C, Ma X, Liu L, Wang JP, Mei QB: The osteoprotective effect of Radix Dipsaci extract in ovariectomized rats. *J Ethnopharmacol* 2009, 123(1):74–81.

51. Wong RW, Rabie AB, Hagg EU: The effect of crude extract from Radix Dipsaci on bone in mice. *Phytother Res* 2007, 21(6):596–598.

52. Zhang R, Hu SJ, Li C, Zhang F, Gan HQ, Mei QB: Achyranthes bidentata root extract prevent OVX-induced osteoporosis in rats. *J Ethnopharmacol* 2012, 139(1):12–18.

53. Chen HY, Lin YH, Wu JC, Chen YC, Yang SH, Chen JL, Chen Tz: Prescription patterns of Chinese herbal products for menopausal syndrome: analysis of a nationwide prescription database. *J Ethnopharmacol* 2011, 137(3):1261–1266.

54. Sun JS, Theriault BL, Anderson GI: The effect of Gu-Sui-Bu (Drynaria fortunei) on bone cell activity. *Am J Chin Med* 2004, 32(5):737–753.

55. Sun JS, Dong GC, Lin CY, Sheu SY, Lin FH, Chen LT, Chang WH, Wang YJ: The effect of Gu-Sui-Bu (Drynaria fortunei J. Sm) immobilized modified calcium hydrogenphosphate on bone cell activities. *Biomaterials* 2003, 24(5):873–882.

56. Kubo M, Matsuda H, Tokuoka K, Ma S, Shiomoto H: Anti-inflammatory activities of methanolic extract and alkaloidal components from Corydalis tuber. *Biol Pharm Bull* 1994, 17(2):262–265.

57. Huang JY, Fang M, Li YJ, Ma YQ, Cai XH: Analgesic effect of Corydalis yanhusuo in a rat model of trigeminal neuropathic pain. *Journal of Southern Medical University* 2010, 30(9):2161–2164.